The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients
Open Access
- 30 July 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 701636
Abstract
Mutation-derived neoantigens are now established as attractive targets for cancer immunotherapy. The field of adoptive T cell transfer (ACT) therapy was significantly reshaped by tumor neoantigens and is now moving towards the genetic engineering of T cells with neoantigen-specific T cell receptors (TCRs). Yet, the identification of neoantigen-reactive TCRs remains challenging and the process needs to be adapted to clinical timelines. In addition, the state of recipient T cells for TCR transduction is critical and can affect TCR-ACT efficacy. Here we provide an overview of the main strategies for TCR-engineering, describe the selection and expansion of optimal carrier cells for TCR-ACT and discuss the next-generation methods for rapid identification of relevant TCR candidates for gene transfer therapy.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Biltema Foundation
This publication has 147 references indexed in Scilit:
- Targeted Genome Editing Across Species Using ZFNs and TALENsScience, 2011
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated TumorCancer Research, 2010
- A Transposon and Transposase System for Human ApplicationMolecular Therapy, 2010
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenBlood, 2009
- Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencingGenome Research, 2009
- Mechanics of T cell receptor gene rearrangementCurrent Opinion in Immunology, 2009
- Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsJournal of Clinical Investigation, 2008
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primatesJournal of Clinical Investigation, 2008
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006